Literature DB >> 19658314

[Surgical treatment for renal cancer metastases].

José L Ruiz-Cerdá1, Fernando Jiménez Cruz.   

Abstract

Complete removal of metastatic lesions can contribute to improve clinical prognosis of renal cancer. Nowadays, it is accepted that surgical extirpation of solitary metastases for patients with renal cancer is the only potential for long-term survival. Provided that the metastases could be technical and functionally resected. This review addresses the current evidence about resecable renal cancer metastases at lung, liver, bone, kidney and other organs. The criteria to consider a patient as candidate for resection of metastases are: control of primary tumor, surgical extirpation feasibility and lack of systemic disease. In patients with synchronous metastases, the surgical extirpation should be performed at the same time than nephrectomy. The clinical prognosis is worse when metastases are asynchronous. After the introduction of novel anti-angiogenic agents, surgery is also justified in patients with good responses. Although, this approach remains in the field of investigation.

Entities:  

Mesh:

Year:  2009        PMID: 19658314     DOI: 10.1016/s0210-4806(09)74194-4

Source DB:  PubMed          Journal:  Actas Urol Esp        ISSN: 0210-4806            Impact factor:   0.994


  3 in total

1.  Information needs and Internet use in urological and breast cancer patients.

Authors:  Beatriz Valero-Aguilera; Clara Bermúdez-Tamayo; José Francisco García-Gutiérrez; Jaime Jiménez-Pernett; José Manuel Cózar-Olmo; Rosario Guerrero-Tejada; Rubén Alba-Ruiz
Journal:  Support Care Cancer       Date:  2014-02       Impact factor: 3.603

2.  Clinical manifestation of RCC leptomeningealcarcinomatosis-A case study.

Authors:  J Y C Huang; S C Tan
Journal:  Int J Surg Case Rep       Date:  2010-11-27

3.  Prolonged survival after sequential multimodal treatment in metastatic renal cell carcinoma: two case reports and a review of the literature.

Authors:  John Syrios; Georgios Kechagias; Nicolas Tsavaris
Journal:  J Med Case Rep       Date:  2012-09-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.